A Phase III, Multicenter, Randomized, Open Label, Clinical study To evaluate Efficacy and Safety of two strengths of Meropenem Plus Tazobactam For the Treatment of Patients with Gram Negative Infection Including Pseudomonas aeruginosa

Trial Profile

A Phase III, Multicenter, Randomized, Open Label, Clinical study To evaluate Efficacy and Safety of two strengths of Meropenem Plus Tazobactam For the Treatment of Patients with Gram Negative Infection Including Pseudomonas aeruginosa

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2016

At a glance

  • Drugs Meropenem/tazobactam (Primary) ; Meropenem
  • Indications Gram-negative infections; Pseudomonal infections
  • Focus Therapeutic Use
  • Sponsors Aqua Vitoe Laboratories
  • Most Recent Events

    • 05 May 2013 Status changed from recruiting to completed as reported by Clinical Trials Registry - India.
    • 12 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top